Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

AveXis.. 2016. AveXis reports interim data from ongoing phase 1 clinical trial of AVXS-101 in spinal muscular atrophy type 1 as presented at the International Annual Congress of the World Muscle Society. Available at: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2210279 (accessed November 10, 2016).

Spark Therapeutics and Pfizer.. 2016. Spark Therapeutics and Pfizer announce updated data from hemophilia B phase 1/2 trial suggesting sustained therapeutic levels of factor IX activity. Available at: http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2219230 (accessed November 10, 2016).

Fidler

. 2016. New data show power, limits of bluebird's gene therapy for blood diseases. Xconomy, November 3. Available at: www.xconomy.com/boston/2016/11/03/new-data-show-power-limits-of-bluebirds-gene-therapy-for-blood-diseases/# (accessed November 11, 2016).

Bluebird bio.. 2016. bluebird bio to present new data from three LentiGlobin™ clinical studies at American Society of Hematology (ASH) Annual Meeting. Available at: http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2219192 (accessed November 11, 2016).

Bluebird bio.. 2016. bluebird bio provides update on LentiGlobin™ programs and research and development strategy at Gene Therapy Day. Available at: http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2211455 (accessed November 11, 2016).

CRISPR Therapeutics.. 2016. Form 10-Q quarterly report for the quarterly period ended September 30, 2016, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Available at: http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=254376&fid=14681735 (accessed November 28, 2016).

Nisen

. 2016. CRISPR's bad IPO timing Is costly. BloombergGadfly, October 20. Available at: https://www.bloomberg.com/gadfly/articles/2016-10-20/crispr-therapeutics-ipo-bad-timing-is-costly (accessed November 8, 2016).

CRISPR Therapeutics.. 2016. Prospectus filed pursuant to Rule 424(b)(4). Available at: http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=254376&fid=14624923 (accessed November 8, 2016).

Siprashvili

, Nguyen

, Gorell

, et. al. 2016. Safety and wound outcomes following genetically corrected. JAMA, 316(17):1808–1817. Available at: http://jamanetwork.com/journals/jama/article-abstract/2576610 (accessed November 8, 2016).

10.

Cell and Gene Therapy Catapult.. 2016. Investment in the cell and gene therapy industry in the UK grows 10x since 2012 to £400m/year. Available at: https://ct.catapult.org.uk/news-media/regulatory-news/press-release-investment-cell-and-gene-therapy-industry-uk-grows-10x-2012 (accessed November 8, 2016).

11.

Baker

, Ali

, Thrasher

. 2016. Impact of BREXIT on UK gene and cell therapy: the need for continued pan-European collaboration. Human Gene Therapy, 27(9), 653–655. Available at: http://online.liebertpub.com/doi/full/10.1089/hum.2016.29033.ahb (accessed November 8, 2016).